Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

In situ gel for breast injection containing rifaximin and preparation method thereof

A technology of in-situ gel and rifaximin, which is applied in the directions of medical preparations containing active ingredients, medical preparations without active ingredients, and pharmaceutical formulas, which can solve the problem of long retention time and limit temperature-sensitive in-situ coagulation. Adhesive application and other issues, to achieve strong adhesion, reduce bacterial resistance, and good biocompatibility

Active Publication Date: 2018-08-17
NANJING DEPOT VETERINARY PHARMA R&D CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thermosensitive in situ gel (thermosensitivein situ gel) has the advantages of convenient use, good biocompatibility, low irritation, strong affinity for mucosal tissue, long residence time, and good rheological characteristics in vitro, and is widely used in pharmaceutical preparations , is a research hotspot in the field of sustained and controlled release preparations in recent years. Although the temperature-sensitive in-situ gel has an excellent sustained-release effect, it is difficult to maintain it for 40-70 days, especially when the main ingredient is dissolved in water. It will also be shortened, which limits the application of thermosensitive in situ gel in the field of prevention and treatment of mastitis in dairy cows

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • In situ gel for breast injection containing rifaximin and preparation method thereof
  • In situ gel for breast injection containing rifaximin and preparation method thereof
  • In situ gel for breast injection containing rifaximin and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1: in vitro antibacterial test

[0033] (1) Test material

[0034] Drugs: rifaximin, neomycin sulfate, lysozyme, neohouttuydin sodium

[0035] Bacterial strains: clinically isolated drug-resistant strains of Staphylococcus aureus, Escherichia coli and Streptococcus agalactiae, common agar medium (self-made), common broth medium (self-made).

[0036] (2) Test method

[0037] 2% rifaximin solution and 0.2% neohouttuydin sodium solution were prepared with DMSO as solvent, and 2% neomycin sulfate solution was prepared with water for injection as solvent.

[0038] Inoculate the suspension of Staphylococcus aureus, Escherichia coli and Streptococcus on the agar medium, place it in a 37°C incubator and cultivate it for 24-48h, pick the grown colony and place it in a medium containing 2 mL of sterilized common broth medium In the test tube, dilute it properly with sterilized physiological saline to a bacterial content of 1.5×10 8 individual / mL. For aseptic opera...

Embodiment 2

[0045] Cyclodextrin inclusion complex of rifaximin

[0046] prescription

[0047] Rifaximin 100g

[0048] Ethyl-β-cyclodextrin 190g

[0049] 50% ethanol aqueous solution 1800mL.

[0050] Preparation method: (a), rifaximin is ultrafinely pulverized, and 90% of the particle size is controlled within 5 μm, and there must be no particles with a particle size larger than 10 μm; (b), 100 g of rifaximin and 190 g of ethyl- Put β-cyclodextrin into a grinder, add 900mL of 50% ethanol aqueous solution, and grind for 30 minutes; (c), add the remaining 900mL of 50% ethanol aqueous solution, stir for 4 hours, spray dry, and pass through a 300-mesh sieve to obtain rifaxime A cyclodextrin inclusion compound is disclosed, the particle size of the cyclodextrin inclusion compound is below 50 μm, and rifaximin exists in the form of inclusion compound in the cyclodextrin inclusion compound.

Embodiment 3

[0052] Rifaximin-Neomycin Sulfate Cyclodextrin Inclusion Complex

[0053] prescription

[0054]

[0055]

[0056] Preparation method: (a), rifaximin is ultrafinely pulverized, and 90% of the particle size is controlled within 5 μm, and there must be no particles with a particle size larger than 10 μm; (b), 100 g of rifaximin, 100 g of neosulfate Put mymycin and 400g of 2,6-diethyl-β-cyclodextrin into a grinder, add 2000mL of 50% ethanol aqueous solution, and grind for 30 minutes; (c), add the remaining 2000mL of 50% ethanol aqueous solution, stir for 5h, and spray dry through a 300-mesh sieve to obtain the rifaximin-neomycin sulfate cyclodextrin inclusion compound, the particle size of the cyclodextrin inclusion compound is below 50 μm, and the rifaximin and neomycin sulfate in the cyclodextrin inclusion compound Elements exist in the form of inclusion complexes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses rifaximin-containing in-situ gel for breast injection. The rifaximin-containing in-situ gel comprises the following components in percentage by mass: 0.1-15% of an active drug component existing in a dispersed way, 0.25-20% of an active drug component existing in an inclusion compound form, 12-30% of poloxamer 407, 0.01-11% of poloxamer 188, 0.01-10% of a polymer drag reduction agent, 0.001-3% of a bacterial inhibitor, a pH regulator for regulating the pH value to 5.5-7.5 and the balance of injection water. The invention also discloses a preparation method of the rifaximin-containing in-situ gel for breast injection. Water is used as a solvent, so that the rifaximin-containing in-situ gel is good in biocompatibility, little in irritation and high in safety, exists in a liquid state under a storage condition, is completely formed within 4-15 seconds after being injected to the breast because of thermal stimulation inside the breast and can be used for effectively treating, preventing and controlling mastitis of milk cows within the whole dry cow period; and in addition, the sustained-release effect is remarkable, and the in-vitro drug release time is long and reaches up to 48 days.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations for animals, and relates to a rifaximin-containing in situ gel for breast injection and a preparation method thereof, in particular to a rifaximin-containing breast injection gel with a suitable phase transition temperature Bit gel and its preparation method. Background technique [0002] Dairy cow mastitis is a common and frequently-occurring disease in dairy farming. It is mainly induced by Staphylococcus aureus, Streptococcus, Escherichia coli, Bacillus cereus, Actinomyces pyogenes, Pseudomonas aeruginosa, and Klebsiella. The incidence of dairy cow mastitis in my country is higher than the world average level, which has seriously restricted the development of dairy cattle breeding industry. In the prevention and treatment of dairy cow mastitis, the treatment of the dry period is an important link in the control of herd mastitis. At this time, the cows are in the weaning period, which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/06A61K31/437A61K47/69A61K47/10A61K31/7036A61P15/14A61P31/04A61K31/185
Inventor 余祖功郭凡溪
Owner NANJING DEPOT VETERINARY PHARMA R&D CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com